Evernow

Inside the Company

Evernow was founded in 2019 by Dr. Alicia Jackson, an MIT‑trained engineer with a background in defense‑sector biotech, to address a systemic gap in women’s midlife healthcare [Crunchbase]. The company operates as a direct‑to‑consumer virtual care platform, headquartered in San Francisco, California, and is structured to deliver telehealth services across the United States [Fierce Healthcare, May 2022]. Jackson’s founding narrative centers on applying a technology‑development mindset to a historically underserved and stigmatized medical transition.

Key operational milestones follow a venture‑scale trajectory. The company launched its core subscription service, offering 24/7 access to menopause‑certified clinicians and personalized treatment plans. In April 2022, Evernow announced a $28.5 million Series A round led by New Enterprise Associates (NEA), with participation from 8VC, Refactor Capital, and a roster of celebrity investors including Gwyneth Paltrow and Cameron Diaz [Fierce Healthcare, May 2022]. This capital infusion was earmarked for scaling clinical operations, marketing, and further product development. More recently, the company has publicized a strategic partnership with Talkspace, aimed at integrating mental health support into its menopause care offering.

Data Accuracy: YELLOW -- Company founding and Series A details are confirmed by multiple news outlets; total funding figure is aggregated from secondary sources.

Under the Hood

Evernow's product is a subscription-based virtual care platform built specifically for women navigating perimenopause and menopause. The core service is delivered through a mobile application, providing 24/7 access to a dedicated medical team of menopause-certified clinicians [PERPLEXITY SONAR PRO BRIEF]. This team creates personalized care plans, which can include both hormonal and non-hormonal therapies, weight management guidance, and prescriptions for symptom relief [PERPLEXITY SONAR PRO BRIEF]. The platform emphasizes evidence-based protocols, particularly for hormone therapy, and markets itself as a safety-oriented alternative to navigating complex treatment options alone [PERPLEXITY SONAR PRO BRIEF].

Access is structured around a monthly membership fee, with pricing confirmed at $49 per month, $129 for three months, or $348 for an annual subscription [USA Today, February 2024]. The subscription includes unlimited messaging with the care team and medication management, though prescription costs may be covered separately by a patient's insurance at a local pharmacy [USA Today, February 2024]. The company has published results from an internal study, reporting a "massive decrease" in symptom severity for members who elected to try menopausal hormone therapy [katiecouric.com].

Specific details about the underlying software stack are not publicly disclosed. However, open roles for a Product Manager and a Designer suggest a continued focus on building and refining the digital patient experience [Wellfound]. The concurrent hiring of Nurse Practitioners and Telehealth Physicians indicates the platform's hybrid model relies on integrating clinical workflows with software to facilitate remote consultations and ongoing support [Evernow, 2026 (retrieved)].

Data Accuracy: GREEN -- Product features and pricing confirmed by multiple press reports and company materials.

Market Research

The market for menopause care is transitioning from a neglected clinical afterthought to a mainstream consumer health category, driven by demographic shifts and a growing willingness to pay for specialized, convenient care. The scale of the underlying demographic is clear: there are approximately 65 million women in the U.S. aged 40 to 65 [U.S. Census Bureau, 2023]. For an analogous market sizing, the global menopause market was valued at $16.4 billion in 2023 and is projected to reach $24.7 billion by 2030, growing at a compound annual rate of 6.0% [Grand View Research, 2024].

Metric	Value
U.S. Women Aged 40-65	65 million
Global Menopause Market 2023	$16.4B
Projected Market 2030	$24.7B

Several demand drivers are coalescing to support growth. The aging of the large millennial cohort into their 40s is creating a sustained influx of new potential users. Concurrently, cultural destigmatization, amplified by celebrity advocacy and media coverage, is increasing awareness and willingness to discuss symptoms openly [The Information, May 2022]. From a clinical perspective, a growing body of evidence supporting the safety and efficacy of hormone therapy for many women is reshaping treatment guidelines and patient demand [Evernow, 2026]. Finally, the broader adoption of telehealth has normalized virtual care for chronic condition management.

The company operates at the intersection of several adjacent markets. It competes with traditional primary care and OB/GYN practices, which remain the default but often provide fragmented, time-limited care. The supplement and wellness market offers non-prescription alternatives but lacks clinical oversight. Mental health platforms, such as Talkspace, address overlapping symptoms like mood changes but do not provide the comprehensive hormone management that is Evernow's core offering. Regulatory forces are generally favorable but carry compliance overhead. The platform must navigate state-by-state telemedicine licensing, prescription drug dispensing laws, and HIPAA privacy requirements.

Data Accuracy: YELLOW -- Market size figures are from public census data and an analogous industry report; specific TAM for digital menopause care is not independently sourced.

Competition and Substitutes

Evernow operates in a femtech segment where competition is defined by a blend of direct digital health peers, adjacent wellness platforms, and the default incumbent: the fragmented, traditional healthcare system.

Company	Positioning	Stage / Funding	Notable Differentiator
Evernow	Virtual, subscription-based menopause care platform for women 40+.	Series A, $52.5M+ (estimated) total.	Strong celebrity investor branding; emphasis on 24/7 access and evidence-based hormone therapy.
Midi Health	Virtual clinic for women in midlife, focusing on perimenopause and menopause.	Series B, $99M total.	Operates with a care-team model; has established employer and health plan partnerships.
Alloy	Digital health company for women 40+, offering menopause and primary care.	Series A, $26M total.	Positioned as a longitudinal primary care partner for women, not solely a menopause clinic.
Gennev	Telehealth and education platform for menopause support.	Seed/Series A, $6.5M+.	Historically strong community and educational content; offers both DTC and enterprise solutions.

Evernow's defensible edge today rests on two pillars: brand capital and clinical focus. The roster of celebrity investors, including Gwyneth Paltrowing Gwyneth Paltrow, Drew Barrymore, and Cameron Diaz, provides a marketing advantage that is difficult and expensive to replicate [The Information, May 2022]. Its second edge is a disciplined, evidence-based focus on hormone therapy. The company's most significant exposure is in distribution channels. While competitors like Midi Health have publicly announced employer and health plan partnerships, Evernow's model remains predominantly direct-to-consumer, reliant on out-of-pocket payments [USA Today, February 2024].

Data Accuracy: YELLOW -- Competitor funding and positioning are partially corroborated by public filings and news reports, but some differentiation details are inferred from company materials and market analysis.

Opportunity

Evernow’s opportunity rests on becoming the default, trusted brand for a generation of women navigating a healthcare transition that has been systematically underserved. The company has anchored its brand on evidence-based, safety-oriented care in a space historically marked by stigma and misinformation [The Information, May 2022]. Its model, built as an all-inclusive subscription service with 24/7 access to certified specialists, is designed to foster deep patient loyalty and recurring revenue [Fierce Healthcare, May 2022].

Scenario	What happens	Catalyst	Why it's plausible
The Integrated Women’s Health Hub	Evernow expands its service stack beyond menopause to address adjacent, high-prevalence conditions in midlife women, becoming a one-stop virtual clinic.	Launch of a second longitudinal care program, validated by proprietary data from its initial menopause study.	The company’s model is built on continuous clinician-patient relationships and subscription retention, creating a natural foundation for cross-selling new care pathways.
The Enterprise & Payer Standard	The company transitions from a pure DTC model to a B2B2C powerhouse, embedding its care protocols into employer health plans and payer networks as a covered benefit.	Securing a flagship partnership with a national health insurer or a Fortune 500 employer with a large female workforce.	The strategic partnership with Talkspace demonstrates an existing playbook for B2B distribution and indicates a move beyond pure consumer payments.

Data Accuracy: YELLOW -- Core opportunity thesis is supported by multiple public sources on model and funding; specific growth scenarios are extrapolated from company strategy and one confirmed partnership.